摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-ethyl-4-hydroxy-5-methylbenzoic acid | 1011264-26-8

中文名称
——
中文别名
——
英文名称
3-ethyl-4-hydroxy-5-methylbenzoic acid
英文别名
3-Ethyl-4-hydroxy-5-methyl-benzoic acid
3-ethyl-4-hydroxy-5-methylbenzoic acid化学式
CAS
1011264-26-8
化学式
C10H12O3
mdl
——
分子量
180.203
InChiKey
OVZIQWZTZMYTMF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-ethyl-4-hydroxy-5-methylbenzoic acid 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下, 以 甲醇二氯甲烷异丙醇 为溶剂, 生成 (S)-1-amino-3-(4-(3-(2-(diethylamino)-6-methylpyridin-4-yl)-1,2,4-oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)propan-2-ol
    参考文献:
    名称:
    Novel S1P1 Receptor Agonists − Part 3: From Thiophenes to Pyridines
    摘要:
    In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P(1) agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P(1) agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P(1) agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P(1), and S1P(3) receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.
    DOI:
    10.1021/jm4014696
  • 作为产物:
    描述:
    2-甲基-6-乙基苯胺sodium chloritesodium dihydrogenphosphate硫酸溶剂黄146 、 sodium nitrite 作用下, 以 二甲基亚砜 为溶剂, 反应 47.0h, 生成 3-ethyl-4-hydroxy-5-methylbenzoic acid
    参考文献:
    名称:
    WO2008/29370
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • [EN] PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS<br/>[FR] DÉRIVÉS DE PYRIDIN-2-YLE UTILISÉS COMME AGENTS IMMUNOMODULATEURS
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2009109872A1
    公开(公告)日:2009-09-11
    The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    这项发明涉及公式(I)的吡啶衍生物,其中A、R1、R2、R3、R4、R5、R6和R7如描述中所述,它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
  • AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
    申请人:Bolli Martin
    公开号:US20100087417A1
    公开(公告)日:2010-04-08
    The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    该发明涉及新型氨基吡啶衍生物,其制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
  • Pyridin-3-yl derivatives as immunomodulating agents
    申请人:Bolli Martin
    公开号:US20100168005A1
    公开(公告)日:2010-07-01
    The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 ; R 6 and A are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    该发明涉及Formula (I)中的吡啶-3-基衍生物,其中R1、R2、R3、R4、R5、R6和A如描述中所述,它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
  • Pyridin-4-yl derivatives as immunomodulating agents
    申请人:Bolli Martin
    公开号:US20100063108A1
    公开(公告)日:2010-03-11
    The invention relates to pyridine derivatives of Formula (I) wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    该发明涉及公式(I)中的吡啶衍生物,其中A、R1、R2、R3、R4、R5和R6如描述中所述,它们的制备以及它们作为药用活性化合物的用途。所述化合物特别作为免疫调节剂。
  • Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists
    申请人:Bolli Martin
    公开号:US08592460B2
    公开(公告)日:2013-11-26
    The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    本发明涉及新型氨基吡啶衍生物,其制备以及其用作药物活性化合物。这些化合物特别作为免疫调节剂。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐